Furie RA, et al. - Authors evaluated the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) who completed the Study of Belimumab in Subjects with SLE 76-week trial. They found that compared to the baseline value, the mean ± SD SDI score increased by 0.4 ± 0.68. They also observed that through study year 7, the overall incidence of treatment-related and serious AEs continued to be stable or declined. Overall, in patients with SLE, the previously observed safety and efficacy profiles of belimumab were confirmed in these long-term exposure results.